181 related articles for article (PubMed ID: 36816982)
1. Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma.
Wieczorek A; Zaniewska-Tekieli A; Ehlert K; Pawinska-Wasikowska K; Balwierz W; Lode H
Front Oncol; 2023; 13():1082771. PubMed ID: 36816982
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
3. Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.
Lode HN; Ladenstein R; Troschke-Meurer S; Struppe L; Siebert N; Zumpe M; Ehlert K; Huber S; Glogova E; Hundsdoerfer P; Eggert A; Zaniewska-Tekieli A; Balwierz W; Wieczorek A
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444475
[TBL] [Abstract][Full Text] [Related]
4. Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience.
Olgun N; Cecen E; Ince D; Kizmazoglu D; Baysal B; Onal A; Ozdogan O; Guleryuz H; Cetingoz R; Demiral A; Olguner M; Celik A; Kamer S; Ozer E; Altun Z; Aktas S
Front Oncol; 2022; 12():1041443. PubMed ID: 36620564
[TBL] [Abstract][Full Text] [Related]
5. Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?
Raiser P; Schleiermacher G; Gambart M; Dumont B; Defachelles AS; Thebaud E; Tandonnet J; Pasqualini C; Proust S; Entz-Werle N; Aerts I; Ndounga-Diakou LA; Petit A; Puiseux C; Khanfar C; Rouger J; Mansuy L; Benadiba J; Millot F; Pluchart C; Laghouati S; Geoerger B; Vassal G; Valteau-Couanet D; Berlanga P
Eur J Cancer; 2024 May; 202():114001. PubMed ID: 38489858
[TBL] [Abstract][Full Text] [Related]
6. Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings-Real-World Data.
Wieczorek A; Żebrowska U; Ussowicz M; Sokół A; Stypińska M; Dembowska-Bagińska B; Pawińska-Wąsikowska K; Balwierz W
J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629294
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
[TBL] [Abstract][Full Text] [Related]
8. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
[TBL] [Abstract][Full Text] [Related]
9. The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
Greenwood KL; Foster JH
Expert Opin Drug Saf; 2018 Dec; 17(12):1257-1262. PubMed ID: 30433831
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy.
Keyel ME; Reynolds CP
Biologics; 2019; 13():1-12. PubMed ID: 30613134
[TBL] [Abstract][Full Text] [Related]
11. Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction.
Cupit-Link M; Federico SM
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760578
[TBL] [Abstract][Full Text] [Related]
12. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
Ploessl C; Pan A; Maples KT; Lowe DK
Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
Edelman MJ; Dvorkin M; Laktionov K; Navarro A; Juan-Vidal O; Kozlov V; Golden G; Jordan O; Deng CQ; Bentsion D; Chouaid C; Dechev H; Dowlati A; Fernández Núñez N; Ivashchuk O; Kiladze I; Kortua T; Leighl N; Luft A; Makharadze T; Min Y; Quantin X;
Lung Cancer; 2022 Apr; 166():135-142. PubMed ID: 35278766
[TBL] [Abstract][Full Text] [Related]
14. High-dose carboplatin-irinotecan-temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma.
Kobushi H; Saida S; Umeda K; Iwai A; Kozuki K; Kubota H; Tanaka K; Obu S; Uchihara Y; Tasaka K; Kato I; Hiramatsu H; Takita J
Pediatr Blood Cancer; 2023 Jul; 70(7):e30331. PubMed ID: 37066594
[TBL] [Abstract][Full Text] [Related]
15. Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor.
Lerman BJ; Li Y; Carlowicz C; Granger M; Cash T; Sadanand A; Somers K; Ranavaya A; Weiss BD; Choe M; Foster JH; Pinto N; Morgenstern DA; Rafael MS; Streby KA; Zeno RN; Mody R; Yazdani S; Desai AV; Macy ME; Shusterman S; Federico SM; Bagatell R
J Clin Oncol; 2023 Jan; 41(3):508-516. PubMed ID: 36206505
[TBL] [Abstract][Full Text] [Related]
16. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
Front Immunol; 2021; 12():690467. PubMed ID: 34367149
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
Mody R; Yu AL; Naranjo A; Zhang FF; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Hank JA; Felder M; Birstler J; Sondel PM; Asgharzadeh S; Glade-Bender J; Katzenstein H; Maris JM; Park JR; Bagatell R
J Clin Oncol; 2020 Jul; 38(19):2160-2169. PubMed ID: 32343642
[TBL] [Abstract][Full Text] [Related]
18. Dinutuximab beta in the treatment of high-risk neuroblastoma: A follow-up of a case series in Bratislava.
Achbergerová M; Hederová S; Hrašková A; Kolenová A
Medicine (Baltimore); 2022 Jan; 101(4):e28716. PubMed ID: 35089239
[TBL] [Abstract][Full Text] [Related]
19. A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood.
Keyel ME; Furr KL; Kang MH; Reynolds CP
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834874
[TBL] [Abstract][Full Text] [Related]
20. Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.
Lode HN; Ehlert K; Huber S; Troschke-Meurer S; Siebert N; Zumpe M; Loibner H; Ladenstein R
Br J Cancer; 2023 Nov; 129(11):1780-1786. PubMed ID: 37813959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
